Commerzbank: Board of Managing Directors presents strategy

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Commerzbank: Board of Managing Directors presents strategy and financial objectives 2020 to the Supervisory Board

Commerzbank Aktiengesellschaft  / Key word(s): Miscellaneous 

29.09.2016 10:34 

Disclosure of an inside information according to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement. 

---------------------------------------------------------------------------

In response to current market rumours, the Board of Managing Directors of Commerzbank AG confirms that it has presented Commerzbank's draft strategic and financial objectives until 2020 to the Supervisory Board for consideration. No decision has yet been taken with regard to the implementation of these objectives. The Board of Managing Directors will decide tomorrow on the strategic objectives after discussions with the Supervisory Board. The objectives presented are as follows: 

By the end of 2020 Commerzbank will have sustainably increased its profitability. As part of the "Commerzbank 4.0" strategy, it will concentrate on its core businesses, digitalise 80% of relevant processes, and thereby achieve significant efficiency gains. Its business will be focused in two customer segments, "Private and Small Business Customers" and "Corporate Clients". The Mittelstandsbank and Corporates & Markets segments will be merged and trading activities in investment banking scaled back. This will reduce earnings volatility and regulatory risk and will free up capital to be invested in core client businesses.

In the context of the decision of the new strategy, goodwill and intangible assets of both Corporates & Markets and Mittelstandsbank will be subjected to an impairment test. This means that most probably around 700 million euros would be written off in the third quarter of 2016. Consequently, the net result would be negative in the third quarter. The write-offs do not affect the Common Equity Tier 1 (CET 1) ratio. In terms of Operating profit, Commerzbank is expecting revenues to be approximately the same as in the second quarter. Loan loss provisions will be considerably higher than in the first two quarters due to ongoing weakness in the shipping markets. Despite the goodwill write-offs, Commerzbank is expecting a small net profit for 2016 as a whole. The CET 1 ratio after full application of Basel 3 will be higher in the third quarter of 2016 than in the previous quarter. The Bank is expecting its Common Equity Tier 1 ratio to stand at nearly 12% at the end of the year, provided no significant market distortions occur. 

Commerzbank is aiming for a net return on tangible equity (RoTE) of at least 6% by the end of 2020. This target is based on the expectation that the interest rate environment will remain challenging. Should the interest rate environment improve, a net return on tangible equity of at least 8% will be achievable. Commerzbank is expecting revenues for 2020 to total between 9.8 and 10.3 billion euros. The cost base is to be reduced to 6.5 billion euros, taking the cost/income ratio to below 66%. In a normalised interest rate environment, revenues could rise to over 11 billion euros and the cost/income ratio could fall to around 60%. 

The Common Equity Tier 1 (CET 1) ratio, after full application of Basel 3, is expected to stay at around 12% and will be above 12% in 2018 taking into account currently foreseeable regulatory developments. For 2020 the Bank expects a ratio of above 13%. 

The focus on the core business, with some business activities being discontinued, and the digitalisation and automation of workflows will lead to staff reductions amounting to around 9,600 full-time positions. The Bank will shortly begin preparatory discussions with the relevant employee representative committees. At the same time, around 2,300 new jobs will be created in areas of business growth. Hence the net number of jobs shed will amount to around 7,300 full-time positions. 

To cover its restructuring costs in the region of 1.1 billion euros, Commerzbank will cease dividend payments for the time being and will retain its full earnings. 

***** 

Disclaimer

This release contains forward-looking statements. Forward-looking statements are statements that are not historical facts. In this release, these statements concern inter alia the expected future business of Commerzbank, efficiency gains and expected synergies, expected growth prospects and other opportunities for an increase in value of Commerzbank as well as expected future financial results, restructuring costs and other financial developments and information. These forward-looking statements are based on the management's current plans, expectations, estimates and projections. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors that may cause actual results and developments to differ materially from any future results and developments expressed or implied by such forward-looking statements. Such factors include the conditions in the financial markets in Germany, in Europe, in the USA and other regions from which Commerzbank derives a substantial portion of its revenues and in which Commerzbank holds a substantial portion of its assets, the development of asset prices and market volatility, especially due to the ongoing European debt crisis, potential defaults of borrowers or trading counterparties, the implementation of its strategic initiatives to improve its business model, particularly to reduce its ACR portfolio, the reliability of its risk management policies, procedures and methods, risks arising as a result of regulatory change and other risks. Forward-looking statements therefore speak only as of the date they are made. Commerzbank has no obligation to update or release any revisions to the forward-looking statements contained in this release to reflect events or circumstances after the date of this release.

Contact: Commerzbank AG Group Communications Tel.: +49 69 136 - 22830 mediarelations@commerzbank.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 387

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 544

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 109

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 411

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 174

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading